A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.

Inclusion Criteria:

Healthy male or non-pregnant female aged ≥ 18 years
Subjects must have provided IRB approved written informed consent
Subjects must be willing and able to understand and comply with the requirements of the protocol, including attendance at the required study visits
Subjects with a clinical diagnosis of stable (at least 6 months) plaque psoriasis involving at least 3% and no more than 12% of the body surface area (BSA). Affected areas should not include the axillae, face, scalp, soles, palms, and intertriginous areas

Exclusion Criteria:

Female Subjects who are pregnant, nursing or planning to become pregnant during study participation.
Females of childbearing potential who do not agree to utilize an adequate form of contraception.
Subjects with a known hypersensitivity to tazarotene, halobetasol propionate, other corticosteroids, or to any ingredients in the study drugs.
Subjects with current diagnosis of unstable forms of psoriasis including guttate, erythrodermic, exfoliative or pustular psoriasis.